HC Wainwright Issues Optimistic Outlook for JSPR Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Investment analysts at HC Wainwright lifted their Q1 2026 EPS estimates for shares of Jasper Therapeutics in a report issued on Tuesday, March 31st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.37) per share for the quarter, up from their previous estimate of ($0.79). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.78) EPS.

Other equities research analysts have also issued research reports about the company. Rodman & Renshaw started coverage on Jasper Therapeutics in a research report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd. Finally, UBS Group initiated coverage on Jasper Therapeutics in a research report on Monday, March 23rd. They issued a “neutral” rating on the stock. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Jasper Therapeutics has an average rating of “Hold” and a consensus target price of $19.88.

Jasper Therapeutics Price Performance

JSPR stock opened at $0.80 on Thursday. The stock has a market capitalization of $22.38 million, a P/E ratio of -0.17 and a beta of 3.20. The business has a 50-day moving average of $1.30 and a 200-day moving average of $1.76. Jasper Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Monday, March 30th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.47.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds have recently modified their holdings of JSPR. Knott David M Jr raised its stake in shares of Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after purchasing an additional 10,000 shares during the period. Acadian Asset Management LLC bought a new position in Jasper Therapeutics in the 1st quarter valued at $46,000. Marex Group plc purchased a new position in Jasper Therapeutics during the second quarter worth about $74,000. Engineers Gate Manager LP bought a new stake in shares of Jasper Therapeutics during the 2nd quarter valued at about $78,000. Finally, Renaissance Technologies LLC boosted its position in shares of Jasper Therapeutics by 9.0% during the 4th quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after acquiring an additional 18,683 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.